155 related articles for article (PubMed ID: 38595897)
1. Frequency of Programmed Death Receptor Ligand 1 Expression and Clinicopathological Factors Associated With Metastatic Triple-Negative Breast Cancer at a Tertiary Cancer Care Centre in South India.
Babu S; Choudhary A; Jacob L; K N L; A H R; L K R; Saldanha S; Amirtham U; C R V
Cureus; 2024 Mar; 16(3):e55880. PubMed ID: 38595897
[TBL] [Abstract][Full Text] [Related]
2. PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC).
Ghosh J; Chatterjee M; Ganguly S; Datta A; Biswas B; Mukherjee G; Agarwal S; Ahmed R; Chatterjee S; Dabkara D
Ecancermedicalscience; 2021; 15():1217. PubMed ID: 34158821
[TBL] [Abstract][Full Text] [Related]
3. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
Front Oncol; 2022; 12():804466. PubMed ID: 35280756
[TBL] [Abstract][Full Text] [Related]
4. A study of triple negative breast cancer at a tertiary cancer care center in southern India.
Lakshmaiah KC; Das U; Suresh TM; Lokanatha D; Babu GK; Jacob LA; Babu S
Ann Med Health Sci Res; 2014 Nov; 4(6):933-7. PubMed ID: 25506489
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
[TBL] [Abstract][Full Text] [Related]
6. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
8. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
Danziger N; Sokol ES; Graf RP; Hiemenz MC; Maule J; Parimi V; Palmieri C; Pusztai L; Ross JS; Huang RSP
Oncologist; 2023 Apr; 28(4):319-326. PubMed ID: 36866462
[TBL] [Abstract][Full Text] [Related]
9. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
[No Abstract] [Full Text] [Related]
10. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
11. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of PDL1 expression in breast cancer.
Sabatier R; Finetti P; Mamessier E; Adelaide J; Chaffanet M; Ali HR; Viens P; Caldas C; Birnbaum D; Bertucci F
Oncotarget; 2015 Mar; 6(7):5449-64. PubMed ID: 25669979
[TBL] [Abstract][Full Text] [Related]
13. Expression of neuroendocrine markers predicts increased survival in triple-negative breast cancer patients.
Xia C; Shen S; Pang J; Chen L; Yan J; Liang Z; Ren X
Front Endocrinol (Lausanne); 2023; 14():1205631. PubMed ID: 38125789
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
15. Role of Taxanes in Triple-Negative Breast Cancer: A Study From Tertiary Cancer Center in South India.
Lakshmaiah KC; Anand A; Babu KG; Dasappa L; Jacob LA; Babu M C S; Lokesh KN; Rudresha AH; Rajeev LK; Saldanha SC; Giri GV; Koppaka D
World J Oncol; 2017 Aug; 8(4):110-116. PubMed ID: 29147445
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
17. CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression.
Boudin L; De Nonneville A; Finetti P; Guittard G; Nunes JA; Birnbaum D; Mamessier E; Bertucci F
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884417
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
[TBL] [Abstract][Full Text] [Related]
20. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.
Huang X; Xie X; Wang H; Xiao X; Yang L; Tian Z; Guo X; Zhang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 Sep; 36(1):129. PubMed ID: 28915924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
